Life Sciences Oligonucleotide CMC,Oligonucleotides

Impurity Analysis of Phosphoramidites for Manufacturing Oligonucleotide Therapeutics

Name: Impurity Analysis of Phosphoramidites for Manufacturing Oligonucleotide Therapeutics
Uploaded: 2023-11-14T15:52:37.228Z

31 Oct 2023

0:00

Play

Backward 10 seconds

Forward 10 seconds

Mute

0:00

Playback speed

Captions

Enter Fullscreen

https://cdn.streamly.video/TIDES_Europe_2023_Streamly_Baner_e7e5c481d8.png

PREVIEW

Join Streamly to watch the full video

Gary HeldStaff Scientist, Analytical Development at Thermo Fisher Scientific

Gary Held, MBA Staff Scientist, Analytical Development Thermo Fisher Scientific Gary Held has been working in the Phosphoramidite and Nucleotide space at Thermo Fisher for almost 20 years. His expertise is in product testing and impurity identification using a number of techniques including LCMS and NMR. He has published several articles and application notes related to impurity formation and control in the amidite supply change and chemical synthesis. Prior experience includes leading analytical development and quality control teams for small molecule API manufacturers.

Join Streamly for free to watch this video

Description

The presentation covers these topics:

Criteria for choosing raw materials for synthetic oligonucleotide therapeutic development and manufacturing;
Phosphoramidites in synthetic oligonucleotide therapeutic development and production;
Synthesis of phosphoramidites and impurity generation and identification;
Identification of impurities in 2’-Fluoro-phosphoramidites from several vendors;
TheraPure™ Phosphoramidties.

Your cart